Business context and reporting period
Ultragenyx Pharmaceutical Inc. filed this Form 10-K for the fiscal year ended December 31, 2015. The company is a clinical-stage biopharmaceutical developer focused on rare and ultra-rare genetic diseases. It had no products approved for sale and generated no revenue. Its clinical pipeline included KRN23 (XLH and TIO), rhGUS (MPS 7), UX007 (LC-FAOD and Glut1 DS), and Ace-ER (GNE myopathy); rhPPCA remained preclinical.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $114.7 million | $46.0 million |
| General and administrative expense | $33.0 million | $10.8 million |
| Total operating expenses | $147.7 million | $56.8 million |
| Net loss | $145.6 million | $59.8 million |
| Net loss per share, basic and diluted | $3.96 | $2.25 |
| Cash, cash equivalents and investments at year-end | $536.3 million | $187.5 million |
| Working capital at year-end | $422.3 million | $180.9 million |
2015 operating cash outflow was $106.0 million, versus $44.6 million in 2014. Investing cash outflow was $292.4 million, largely reflecting purchases of investments; financing cash inflow was $467.6 million, principally from public stock offerings. The company reported $28.5 million in total liabilities and no debt line item on the balance sheet. With no revenue, operating margins are not meaningful. Cash and investments were primarily held in cash equivalents and available-for-sale securities; management said a hypothetical 10% interest-rate change would not have had a material financial-statement impact.
Fourth-quarter 2015 operating expenses were $56.2 million and net loss was $55.2 million, or $1.42 per share, compared with fourth-quarter 2014 operating expenses of $16.9 million and net loss of $16.7 million, or $0.52 per share.
Material changes versus prior comparable periods
- Annual net loss increased to $145.6 million from $59.8 million; operating expenses rose 160% year over year.
- R&D expense increased 150%, reflecting advancement of clinical programs, manufacturing and regulatory work, higher support costs and a $10.0 million Arcturus collaboration upfront fee expensed in Q4.
- G&A expense increased 205%, driven by headcount, professional services, commercial planning and stock-based compensation.
- Cash and investments increased substantially following 2015 equity offerings that generated $461.1 million net proceeds. Year-end common shares outstanding were 38.9 million, up from 31.9 million a year earlier.
Outlook, management commentary, risks and unusual items
Management expected losses and R&D spending to rise as programs progressed, and said additional capital would likely be needed over time. It cited existing capital balances, possible equity or debt financing, and strategic collaborations as potential funding sources. The filing did not provide revenue or earnings guidance.
- Development milestones: KRN23 adult XLH Phase 3 began in December 2015; pediatric XLH data and a possible EU conditional marketing application were anticipated in 2016. rhGUS Phase 3 data were expected mid-2016. UX007 Glut1 DS Phase 2 data were expected in the second half of 2016, with a movement-disorder Phase 3 planned for that period; an LC-FAOD Phase 3 was planned for 2017. Ace-ER Phase 3 data were expected in 2017; the EMA opinion on its conditional application was expected in the second half of 2016. These are management expectations, not guaranteed outcomes.
- Clinical evidence and safety: Interim pediatric XLH results showed improvements in rickets measures through 40 weeks, with mostly mild treatment-related events and one serious event considered possibly related. UX007 LC-FAOD interim findings came from a small, open-label, uncontrolled study; gastrointestinal events were common and one serious event was considered related. Ace-ER’s EU application relied on a small Phase 2 study that was not designed as a pivotal trial. The filing cautions that early, investigator-sponsored and uncontrolled results may not be confirmed in controlled studies.
- Key risks: Clinical and regulatory outcomes remain uncertain; rare-disease enrollment and market size may be limited; pricing, reimbursement and competition could constrain adoption. The company relies on collaborators and third-party manufacturers, including KHK as KRN23 supplier, and disclosed single-source supply and commercial-scale manufacturing risks. Patent coverage is incomplete for some candidates.
- Unusual items and contingencies: The $10.0 million Arcturus upfront fee was expensed in 2015. The filing reported no material legal proceedings and no material off-balance-sheet arrangements. It disclosed $33.3 million in binding operating-lease and manufacturing/service commitments. No income-tax provision was recorded; deferred tax assets were fully offset by a valuation allowance.
Most important facts for investors to verify
- Whether scheduled 2016–2017 trial readouts and regulatory submissions occurred, and whether results support approval.
- How quickly cash is consumed as clinical, manufacturing and commercialization expenses increase; the company used $106.0 million in operating cash in 2015.
- Whether clinical benefits and safety signals from small or uncontrolled studies are confirmed in pivotal trials.
- Whether KHK and other contract manufacturers can provide adequate, compliant supply, and whether secondary sources are secured where needed.
- How equity issuance, stock-based compensation and future financing affect dilution; also verify the terms and milestones in collaboration and license agreements.
Controls and audit
Management and Ernst & Young LLP concluded that internal control over financial reporting was effective as of December 31, 2015. The auditor issued unqualified opinions on the financial statements and internal controls.